| Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α R Ravi, B Mookerjee, ZM Bhujwalla, CH Sutter, D Artemov, Q Zeng, ... Genes & development 14 (1), 34-44, 2000 | 1683 | 2000 |
| Conversion of Bcl-2 to a Bax-like death effector by caspases EHY Cheng, DG Kirsch, RJ Clem, R Ravi, MB Kastan, A Bedi, K Ueno, ... Science 278 (5345), 1966-1968, 1997 | 1605 | 1997 |
| Polymeric nanoparticle-encapsulated curcumin (" nanocurcumin"): a novel strategy for human cancer therapy S Bisht, G Feldmann, S Soni, R Ravi, C Karikar, A Maitra, A Maitra Journal of nanobiotechnology 5, 1-18, 2007 | 1425 | 2007 |
| Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy M Keidar, R Walk, A Shashurin, P Srinivasan, A Sandler, S Dasgupta, ... British journal of cancer 105 (9), 1295-1301, 2011 | 860 | 2011 |
| Notch signaling induces cell cycle arrest in small cell lung cancer cells V Sriuranpong, MW Borges, RK Ravi, DR Arnold, BD Nelkin, SB Baylin, ... Cancer research 61 (7), 3200-3205, 2001 | 586 | 2001 |
| Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB R Ravi, G Bedi, LW Engstrom, Q Zeng, B Mookerjee, C Gélinas, EJ Fuchs, ... Nature cell biology 3 (4), 409-416, 2001 | 462 | 2001 |
| Magnetic resonance molecular imaging of the HER-2/neu receptor D Artemov, N Mori, R Ravi, ZM Bhujwalla Cancer research 63 (11), 2723-2727, 2003 | 339 | 2003 |
| Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy R Ravi, KA Noonan, V Pham, R Bedi, A Zhavoronkov, IV Ozerov, ... Nature communications 9 (1), 741, 2018 | 288 | 2018 |
| Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors E Izumchenko, K Paz, D Ciznadija, I Sloma, A Katz, D Vasquez-Dunddel, ... Annals of Oncology 28 (10), 2595-2605, 2017 | 277 | 2017 |
| ‘The metabolism of tumours’: 70 years later GL Semenza, D Artemov, A Bedi, Z Bhujwalla, K Chiles, D Feldser, ... The Tumour Microenvironment: Causes and Consequences of Hypoxia and Acidity …, 2001 | 277 | 2001 |
| Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer S Bisht, M Mizuma, G Feldmann, NA Ottenhof, SM Hong, D Pramanik, ... Molecular cancer therapeutics 9 (8), 2255-2264, 2010 | 264 | 2010 |
| A high‐fat diet and regulatory T cells influence susceptibility to endotoxin‐induced liver injury X Ma, J Hua, AR Mohamood, ARA Hamad, R Ravi, Z Li Hepatology 46 (5), 1519-1529, 2007 | 222 | 2007 |
| Cold atmospheric plasma treatment selectively targets head and neck squamous cell carcinoma cells R Guerrero-Preston, T Ogawa, M Uemura, G Shumulinsky, BL Valle, ... International journal of molecular medicine 34 (4), 941-946, 2014 | 220 | 2014 |
| p53-mediated repression of nuclear factor-κB RelA via the transcriptional integrator p300 R Ravi, B Mookerjee, Y Van Hensbergen, GC Bedi, A Giordano, ... Cancer research 58 (20), 4531-4536, 1998 | 205 | 1998 |
| NF-κB in cancer—a friend turned foe R Ravi, A Bedi Drug resistance updates 7 (1), 53-67, 2004 | 201 | 2004 |
| Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells JC Byrd, C Shinn, R Ravi, CR Willis, JK Waselenko, IW Flinn, NA Dawson, ... Blood, The Journal of the American Society of Hematology 94 (4), 1401-1408, 1999 | 199 | 1999 |
| Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of solublefactors that induce apoptosis and … G Niu, KH Shain, M Huang, R Ravi, A Bedi, WS Dalton, R Jove, H Yu Cancer research 61 (8), 3276-3280, 2001 | 194 | 2001 |
| Selective radiosensitization of p53–deficient cells by caffeine–mediated activation of p34cdc2 kinase SL Yao, AJ Akhtar, KA Mckenna, GC Bedi, D Sidransky, M Mabry, R Ravi, ... Nature medicine 2 (10), 1140-1143, 1996 | 187 | 1996 |
| Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-xL R Ravi, A Bedi Cancer research 62 (6), 1583-1587, 2002 | 185 | 2002 |
| CD95 (Fas)-induced caspase-mediated proteolysis of NF-κB R Ravi, A Bedi, EJ Fuchs, A Bedi Cancer research 58 (5), 882-886, 1998 | 177 | 1998 |
